Results 131 to 140 of about 204,163 (273)

Diagnostic accuracy of procalcitonin, interleukin-6 and interleukin-8 for predicting Gram-negative bacteremia in febrile neutropenia patients with acute lymphoblastic leukemia

Acta Medica Lituanica, 2015
Background. Currently available biomarkers are not specific and sensitive enough for early detection of bacterial infection in patients with cancer who have febrile neutropenia. The objective of this study was to assess diagnostic accuracy of interleukin-
Vincas Urbonas, Audronė Eidukaitė
doaj   +1 more source

Challenges of Dengue in Hematological Disease Patients: Descriptive Analysis From the DANGO Registry During the 2023–2024 Outbreak in Argentina

Transplant Infectious Disease, EarlyView.
During the 2023–2024 Argentine dengue outbreak, 33 patients with hematological disease showed high complication rates, frequent hospitalization (64%), severe thrombocytopenia (90%), and 6% dengue‐attributable mortality. Transfusion‐associated cases were documented.
Gustavo Adolfo Méndez, Carla Niveyro, Pedro Andrés Villalba Apestegui, Victoria Isabel Martin, Lucila María Compañy Kec, María Cynthia Tomasino, Mariana del Carmen del Marull, Haydee Ingrid Bernard, Claudia Patricia Lorena Fernández, Flavia Marcela Pelech, Maria Fernanda Tosin, María Fernanda González‐Hobecker, Karen Beatrice Duranona, Angela Daiana Jara, Justus Cornely, Oliver A. Cornely, Jon Salmanton‐García   +16 more
wiley   +1 more source

NEUTROPENIA FEBRIL

, 2021
DAYANE KETLYN DA CUNHA SANTOS, JOSÉ FONTES JÚNIOR, JOSÉ CLEYTON DE OLIVEIRA SANTOS   +2 more
openaire   +2 more sources

Delayed Gastric Bleeding in a Patient With Chronic Myeloid Leukemia: A Case of Post‐Biopsy Bleeding

DEN Open, Volume 7, Issue 1, April 2027.
The presence of underlying conditions, particularly malignancies such as myeloproliferative disorders, may increase the risk of delayed bleeding following gastric mucosal biopsy, and similar cases warrant careful accumulation and evaluation in future. ABSTRACT A 76‐year‐old man was referred to our hospital for evaluation of anemia.
Yoko Kosaka, Hiromichi Yamane, Hidekazu Nakanishi, Nagio Takigawa   +3 more
wiley   +1 more source

A case of parvovirus B19 infection mimicking mumps virus infection in a healthy adult

European Journal of Case Reports in Internal Medicine
Introduction: Human parvovirus B19 infection classically manifests as erythema infectiosum in children, but in adults the clinical spectrum is diverse and often atypical.
Hiraku Sedogawa, Yoko Suwa, Masakazu Nitta, Yuki Sugito, Yuki Togawa, Daisuke Tomita   +5 more
doaj   +1 more source

CPX‐351 in High‐Risk Relapsed Pediatric Acute Leukemia: Real‐World Phase 1 Data Establishing the FDA‐Approved Dose

Pediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Background/Objectives Outcomes for pediatric relapsed/refractory (R/R) acute myeloid leukemia (AML) remain dismal. CPX‐351, a liposomal formulation of cytarabine and daunorubicin, may have less off‐target toxicities than traditional chemotherapies and has shown improved outcomes for adults with newly diagnosed therapy‐related AML.
Jonathan D. Bender, Lauren Pommert, Lori R. Backus, Andrea Bidwell, Courtney Blank, Erin H. Breese, Karen C. Burns, Adam Lane, Lynn H. Lee, Benjamin Mizukawa, Robin E. Norris, Maureen M. O'Brien, Daniel Peck, Christine Phillips, Thomas D. Ryan, Jennifer Young, Michael Absalon, John P. Perentesis   +17 more
wiley   +1 more source

Febrile Neutropenia pada Pasien Pascakemoterapi [PDF]

, 2017
Febrile neutropenia (FN) is one of the side effects caused by chemotherapy due to hematopoetic suppression that cause neutropenia and other triggerring factors such as infection.
BUDIANA, I. N. (I), FEBIANI, M. (MELINDA)   +1 more
core  

Age‐Dependent Differences in Canakinumab Safety: A Comprehensive Pharmacovigilance Analysis Using the FAERS Database

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT While the efficacy of canakinumab, an anti‐interleukin‐1β monoclonal antibody, is well‐established, its safety profile, particularly across different age groups, remains inadequately explored. Using the FDA Adverse Event Reporting System (FAERS) database, this study evaluated postmarketing safety by analyzing adverse event (AE) reports from ...
Youyang Wang, Ngasin Lam, Xiaoming Huang, Yang Jiao   +3 more
wiley   +1 more source

Purpuric targetoid eruption revealing disseminated mucormycosis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Francisco Mano, João Teixeira
wiley   +1 more source

Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis

American Journal of Hematology, Volume 101, Issue 5, Page 986-997, May 2026.
ABSTRACT Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed.
Nancy L. Bartlett, Laurie H. Sehn, Sarit Assouline, Pratyush Giri, John Kuruvilla, Stephen J. Schuster, Sung‐Soo Yoon, Keith Fay, Georg Hess, Martin Dreyling, Norma C. Gutierrez, Eva Cybulski, Fidelis Sabalvaro, Elicia Penuel, Vanda Teodoro, Samuel Tracy, Denison Kuruvilla, Joseph Chen, Volker Wiebking, Michael C. Wei, L. Elizabeth Budde   +20 more
wiley   +1 more source